WallStSmart

Alamar Biosciences, Inc. Common Stock (ALMR)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 40614% more annual revenue ($35.48B vs $87.16M). MDT leads profitability with a 13.0% profit margin vs -49.9%. MDT earns a higher WallStSmart Score of 61/100 (C+).

ALMR

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -1.23

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ALMR.

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALMR2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
98.9%10/10

Revenue surging 98.9% year-over-year

Debt/EquityHealth
-1.9110/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

ALMR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.52B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-33.6%2/10

ROE of -33.6% — below average capital efficiency

Free Cash FlowQuality
$-20.95M2/10

Negative free cash flow — burning cash

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALMR

The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 98.9% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : ALMR

The primary concerns for ALMR are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ALMR profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

ALMR is growing revenue faster at 98.9% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (61/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alamar Biosciences, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases, leveraging its proprietary technologies to enhance patient care and treatment outcomes. The company's advanced platform offers rapid and accurate testing capabilities aimed at significantly improving clinical decision-making processes. With a strong commitment to research and development, Alamar is poised to address unmet medical needs within the healthcare sector, presenting an attractive opportunity for institutional investors looking to capitalize on the growth potential in the diagnostics market.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?